Drug Profile
Xisomab 3G3 - Aronora
Alternative Names: AB 022; AB 023; Anti-factor XI Monoclonal Antibody Xisomab 3G3; Anti-FXI Antibody Xisomab 3G3; Mab 14E11 - Aronora; XISOMAB; Xisomab3G3Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Oregon Health & Science University
- Developer Aronora
- Class Anti-infectives; Antiseptics; Antithrombotics; Cardiovascular therapies; Monoclonal antibodies; Recombinant proteins
- Mechanism of Action Factor XI inhibitors; Factor XII inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Thrombosis
- No development reported Cardiovascular disorders; Neurological disorders; Sepsis
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for research development in Neurological-disorders in USA (Parenteral)
- 10 Dec 2022 Efficacy and adverse events data from a phase II trial in Thrombosis (Prevention) presented at the at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
- 05 Nov 2021 Aronora in collaboration with Oregon Health and Science University terminates a phase II trial for Thrombosis (Prevention) in USA (IV), due to an IP manufacturing issue (NCT04465760)